OpenURL Connection Search

Select item for more details and to access through your institution.

Molecular Targeted Therapy in Ovarian Cancer: What is on the Horizon?
Published in:
2011
By:
- Kalachand, Roshni;
- Hennessy, Bryan T.;
- Markman, Maurie
Publication type:
Journal Article
BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.
Published in:
2022
By:
- Cremona, Mattia;
- Vandenberg, Cassandra J.;
- Farrelly, Angela M.;
- Madden, Stephen F.;
- Morgan, Clare;
- Kalachand, Roshni;
- McAlpine, Jessica N.;
- Toomey, Sinead;
- Huntsman, David G.;
- Grogan, Liam;
- Breathnach, Oscar;
- Morris, Patrick;
- Carey, Mark S.;
- Scott, Clare L.;
- Hennessy, Bryan T.
Publication type:
journal article
Bortezomib-induced reversible posterior leucoencephalopathy syndrome.
Published in:
2008
By:
- Kelly, Kevin;
- Kalachand, Roshni;
- Murphy, Philip
Publication type:
Other
Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).
Published in:
Molecular & Clinical Oncology, 2022, v. 16, n. 2, p. 1, doi. 10.3892/mco.2021.2472
By:
- HAMED, RUBA A.;
- MARKS, SAM;
- MCELLIGOTT, HELEN;
- KALACHAND, ROSHNI;
- IBRAHIM, HAWA;
- ATYANI, SAID;
- KORPANTY, GREG;
- OSMAN, NEMER
Publication type:
Article
BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.
Published in:
2020
By:
- Kalachand, Roshni D;
- Stordal, Britta;
- Madden, Stephen;
- Chandler, Benjamin;
- Cunningham, Julie;
- Goode, Ellen L;
- Ruscito, Ilary;
- Braicu, Elena I;
- Sehouli, Jalid;
- Ignatov, Atanas;
- Yu, Herbert;
- Katsaros, Dionyssios;
- Mills, Gordon B;
- Lu, Karen H;
- Carey, Mark S;
- Timms, Kirsten M;
- Kupryjanczyk, Jolanta;
- Rzepecka, Iwona K;
- Podgorska, Agnieszka;
- McAlpine, Jessica N
Publication type:
journal article
RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Published in:
2016
By:
- Toomey, Sinead;
- Eustace, Alex J.;
- Pritzker, Laura B.;
- Pritzker, Ken P. H.;
- Fay, Joanna;
- O'Grady, Anthony;
- Cummins, Robert;
- Grogan, Liam;
- Kennedy, John;
- O'Connor, Darran;
- Young, Leonie;
- Kay, Elaine W.;
- O'Donovan, Norma;
- Gallagher, William M.;
- Kalachand, Roshni;
- Crown, John;
- Hennessy, Bryan T.
Publication type:
Letter

Found: 6

Molecular Targeted Therapy in Ovarian Cancer: What is on the Horizon?

BRCA mutations lead to XIAP overexpression and sensitise ovarian cancer to inhibitor of apoptosis (IAP) family inhibitors.

Bortezomib-induced reversible posterior leucoencephalopathy syndrome.

Inoperable de novo metastatic colorectal cancer with primary tumour in situ: Evaluating discordant responses to upfront systemic therapy of the primary tumours and metastatic sites and complications arising from primary tumours (experiences from an Irish Cancer Centre).

BRCA1 Promoter Methylation and Clinical Outcomes in Ovarian Cancer: An Individual Patient Data Meta-Analysis.

RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.